| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.
|
Cancer Discov
|
2012
|
2.31
|
|
2
|
Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
|
Cancer Res
|
2010
|
1.91
|
|
3
|
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
|
Neoplasia
|
2010
|
1.70
|
|
4
|
STAT3 is necessary for proliferation and survival in colon cancer-initiating cells.
|
Cancer Res
|
2011
|
1.63
|
|
5
|
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
|
Clin Cancer Res
|
2010
|
1.50
|
|
6
|
Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells.
|
J Biol Chem
|
2010
|
1.28
|
|
7
|
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.
|
Mol Cancer
|
2010
|
1.27
|
|
8
|
JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells.
|
Cancer Res
|
2013
|
1.19
|
|
9
|
Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling.
|
Neoplasia
|
2011
|
1.19
|
|
10
|
Design, synthesis, and studies of small molecule STAT3 inhibitors.
|
Bioorg Med Chem Lett
|
2007
|
1.18
|
|
11
|
Characterization of STAT3 activation and expression in canine and human osteosarcoma.
|
BMC Cancer
|
2009
|
1.10
|
|
12
|
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
|
Mol Cancer
|
2010
|
1.05
|
|
13
|
New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells.
|
Cancer Sci
|
2009
|
1.01
|
|
14
|
New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells.
|
BMC Cancer
|
2009
|
1.00
|
|
15
|
Modulation of DNA methylation by a sesquiterpene lactone parthenolide.
|
J Pharmacol Exp Ther
|
2009
|
0.99
|
|
16
|
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
|
J Steroid Biochem Mol Biol
|
2005
|
0.99
|
|
17
|
Structure-activity relationship studies of curcumin analogues.
|
Bioorg Med Chem Lett
|
2009
|
0.97
|
|
18
|
The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.
|
PLoS One
|
2011
|
0.96
|
|
19
|
Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
|
PLoS One
|
2012
|
0.95
|
|
20
|
Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.
|
Sci Signal
|
2014
|
0.95
|
|
21
|
The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.
|
BMC Cancer
|
2011
|
0.93
|
|
22
|
Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
|
Int J Oncol
|
2011
|
0.92
|
|
23
|
Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
|
Br J Pharmacol
|
2009
|
0.92
|
|
24
|
Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation.
|
Biol Pharm Bull
|
2002
|
0.91
|
|
25
|
Fetal alcohol exposure alters neurosteroid levels in the developing rat brain.
|
J Neurochem
|
2004
|
0.91
|
|
26
|
A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.
|
Int J Cancer
|
2011
|
0.90
|
|
27
|
Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells.
|
Anticancer Drugs
|
2009
|
0.88
|
|
28
|
LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells.
|
Anticancer Res
|
2011
|
0.86
|
|
29
|
Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
|
FEBS J
|
2013
|
0.85
|
|
30
|
Synthesis of 4'-hydroxy-3'-piperidinomethylchalcone derivatives and their cytotoxicity against PC-3 cell lines.
|
Arch Pharm (Weinheim)
|
2007
|
0.85
|
|
31
|
Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416.
|
Bioorg Med Chem
|
2006
|
0.85
|
|
32
|
Inhibitors of NF-kappaB derived from thalidomide.
|
Bioorg Med Chem Lett
|
2007
|
0.83
|
|
33
|
Anticancer activity and SAR studies of substituted 1,4-naphthoquinones.
|
Bioorg Med Chem
|
2013
|
0.83
|
|
34
|
Niclosamide Analogs for Treatment of Ovarian Cancer.
|
Int J Gynecol Cancer
|
2015
|
0.82
|
|
35
|
Immunohistochemical analysis of steroid sulfatase in human tissues.
|
J Steroid Biochem Mol Biol
|
2007
|
0.82
|
|
36
|
Structure-activity relationships studies of the anti-angiogenic activities of linomide.
|
Bioorg Med Chem Lett
|
2003
|
0.81
|
|
37
|
Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library.
|
ACS Comb Sci
|
2011
|
0.80
|
|
38
|
Evaluation of the cytotoxicity of some mono-mannich bases and their corresponding azine derivatives against androgen-independent prostate cancer cells.
|
Arzneimittelforschung
|
2006
|
0.80
|
|
39
|
Synthesis and cytotoxicity of novel 3-aryl-1-(3'-dibenzylaminomethyl-4'-hydroxyphenyl)-propenones and related compounds.
|
Chem Pharm Bull (Tokyo)
|
2008
|
0.79
|
|
40
|
Neurosteroid paradoxical enhancement of paired-pulse inhibition through paired-pulse facilitation of inhibitory circuits in dentate granule cells.
|
Neuropharmacology
|
2005
|
0.79
|
|
41
|
A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models.
|
Breast Cancer Res Treat
|
2007
|
0.78
|
|
42
|
Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells.
|
Steroids
|
2002
|
0.78
|
|
43
|
Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle.
|
Bioorg Med Chem Lett
|
2013
|
0.77
|
|
44
|
Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer.
|
Anticancer Res
|
2008
|
0.76
|
|
45
|
The actions of a charged melatonin receptor ligand, TMEPI, and an irreversible MT2 receptor agonist, BMNEP, on mouse hippocampal evoked potentials in vitro.
|
Life Sci
|
2004
|
0.76
|
|
46
|
Inhibition of steroid sulfatase activity and cell proliferation in ZR-75-1 and BT-474 human breast cancer cells by KW-2581 in vitro and in vivo.
|
Breast Cancer Res Treat
|
2006
|
0.76
|
|
47
|
Antiproliferative activities and SAR studies of substituted anthraquinones and 1,4-naphthoquinones.
|
Bioorg Med Chem Lett
|
2013
|
0.75
|
|
48
|
Structure-activity relationship studies of thalidomide analogs with a taxol-like mode of action.
|
Bioorg Med Chem Lett
|
2013
|
0.75
|
|
49
|
Solid-phase synthesis of thalidomide and its analogues.
|
J Comb Chem
|
2002
|
0.75
|
|
50
|
Design, synthesis and biological studies of novel tubulin inhibitors.
|
Bioorg Med Chem Lett
|
2013
|
0.75
|
|
51
|
Biological activity of 1-aryl-3-phenethylamino-1-propanone hydrochlorides and 3-aroyl-4-aryl-1-phenethyl-4-piperidinols on PC-3 cells and DNA topoisomerase I enzyme.
|
Z Naturforsch C
|
2011
|
0.75
|